Designed to be completely sheer, absorbing beautifully without leaving a chalky or gray residue
GI upset, headache, fatigue, and dizziness
Time to Results: Noticeable Appetite Reduction: GLP-1s (semaglutide, tirzepatide): 1-2 weeks Phentermine: 1-3 days Phentermine-topiramate: 1-2 weeks Naltrexone-bupropion: 4-8 weeks Orlistat: Doesnt reduce appetite Measurable Weight Loss: Tirzepatide: 5-8% by week 20, 15-22% by week 72 Semaglutide: 5-7% by week 20, 10-15% by week 68 Phentermine-topiramate: 5-6% by week 28 Others: 3-5% by week 24-28 GLP-1s produce steady, sustained weight loss over 16-20 months
According to the Summary of Product Characteristics (SmPCs), GLP-1 medications commonly cause nausea (reported in approximately 20-40% of patients with semaglutide and 12-21% with dulaglutide), vomiting, and diarrhoea, particularly during initial treatment and dose escalation
The GIP component appears to enhance insulin sensitivity in fat tissue, improve lipid metabolism, and potentially increase energy expenditure in ways that pure GLP-1 agonists cannot match
